{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:00:57Z","timestamp":1787313657234,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>Eltrombopag is approved for the treatment of chronic immune thrombocytopenia purpura (ITP) in pediatric patients 1 year and older who have demonstrated an insufficient response to corticosteroids and intravenous immunoglobulin. We present the case of a 2-year-old boy with chronic immune thrombocytopenia purpura who developed life-threatening adverse effects of acute liver failure, metabolic acidosis and encephalopathy with standard drug dosing. To our knowledge, this is the first case of eltrombopag-induced hepatic encephalopathy highlighting the critical need for prescribers to exercise caution when prescribing eltrombopag in the pediatric setting.<\/jats:p>","DOI":"10.1097\/mph.0000000000002300","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T16:22:55Z","timestamp":1630945375000},"page":"e453-e455","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Eltrombopag-induced Metabolic Acidosis and Hepatic Encephalopathy in Pediatric ITP"],"prefix":"10.1097","volume":"44","author":[{"given":"Erin","family":"Hermann","sequence":"first","affiliation":[{"name":"Caylor School of Nursing, Lincoln Memorial University, Knoxville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Ferdjallah","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"R1-20250805","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5482\/HAMO-16-06-0017","article-title":"Diagnosis and management of immune thrombocytopenia in childhood","volume":"37","author":"K\u00fchne","year":"2017","journal-title":"Hamostaseologie"},{"key":"R2-20250805","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","article-title":"Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study","volume":"2","author":"Bussel","year":"2015","journal-title":"Lancet Haematol"},{"key":"R3-20250805","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40265-016-0581-4","article-title":"Eltrombopag: a review in paediatric chronic immune thrombocytopenia","volume":"76","author":"Burness","year":"2016","journal-title":"Drugs"},{"key":"R4-20250805","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/bloodadvances.2017010660","article-title":"Eltrombopag for use in children with immune thrombocytopenia","volume":"2","author":"Kim","year":"2018","journal-title":"Blood Adv"},{"key":"R5-20250805","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/2042098618769587","article-title":"Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety","volume":"9","author":"Gonzalez-Porras","year":"2018","journal-title":"Ther Adv Drug Saf"},{"key":"R6-20250805","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"R7-20250805","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","article-title":"Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial","volume":"386","author":"Grainger","year":"2015","journal-title":"Lancet"},{"key":"R8-20250805","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/FTD.0000000000000522","article-title":"Eltrombopag-induced acute liver failure in a pediatric patient: a pharmacokinetic and pharmacogenetic analysis","volume":"40","author":"Marano","year":"2018","journal-title":"Ther Drug Monit"},{"key":"R9-20250805","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T01:00:50Z","timestamp":1754355650000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002300","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"assertion":[{"value":"2021-03-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}